ongoing trials trial from www.clinicaltrials.gov SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes - Phase 2|Phase 3 - Not yet recruiting Year: 2023 Date: December 30, 2023 Author: Amir Moheet|University of Minnesota Source https://ClinicalTrials.gov/show/NCT06149793 Study design (if review, criteria of inclusion for studies) Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment Participants Cystic Fibrosis-related Diabetes|Cystic Fibrosis - 18 Years and older (Adult, Older Adult) Interventions Drug: Empagliflozin|Other: Placebo Control Outcome measures Feasibility, safety, tolerability